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Introduction
Older people residing in long-term care are living the last 
years of their lives (1). They are likely to have cognitive 
impairment, deficits in physical functioning, and multiple 
coexisting diseases (1, 2). Their diseases are often chronic (2), 
and thus, the aim of the care is in most cases palliative, i.e. 
to maintain or improve quality of life (QoL). Health-related 
quality of life (HRQoL), recognized as a relevant aspect of 
QoL, consists of physical, emotional, and social dimensions 
associated with a person’s illnesses and their treatment (3).  
Potentially inappropriate medications are widely used among 
older people living in long-term care facilities (4, 5). Most 
drugs with anticholinergic properties (DAPs) are considered 
potentially inappropriate according to American Geriatrics 
Society Beers criteria (6), and thus, should be avoided in older 
adults.  Despite this recommendation, DAPs remain frequently 
used among older nursing home residents (7-11).  DAPs may 
cause adverse effects on both central and peripheral nervous 
systems (12).  Dry mouth, dry eyes, constipation, dizziness, 
cognitive decline, and falls are some of the common adverse 
effects (13, 14). Several studies have reported an association 
between anticholinergic burden and physical impairment (15). 
In a recently published study, even a relationship between 
use of certain DAPs and increased risk of dementia has been 
suggested (16). Polypharmacy among older people living in 
long-term care is common (17), leading easily to a situation in 
which several DAPs are present, increasing the anticholinergic 
burden.  Unwanted side-effects tend to increase hand in hand 
with greater anticholinergic burden (18).
There is a scarcity of studies exploring the relationship 
between anticholinergic drug use and HRQoL in older people, 
and the results are somewhat inconclusive. Studies among 
community dwelling older people have reported an association 
between anticholinergic drug use and the lower physical 
component score of HRQoL according to SF-12/SF-36 (19, 
20).  In studies among older long-term care residents with high 
prevalence of cognitive impairment, exposure to anticholinergic 
and sedative drugs defined by the Drug Burden Index has 
shown to have an inverse association with QoL (5, 21). 
However, in one American study investigating a nursing home 
population, no association between anticholinergic burden and 
engagement in activities, an important indicator of QoL, was 
observed (7). There is some evidence, that among older long-
term care residents DAP use is associated with decreased well-
being, which can be considered an aspect of HRQoL (22, 23).
Despite the importance of the topic, limited research exists 
on the association between DAP use and HRQoL among 
long-term care residents. Our hypothesis was that greater 
anticholinergic burden would have an association with lower 
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HRQoL. The rationale behind our hypothesis was that the 
common side-effects of DAPs may be associated with lower 
HRQoL. Especially residents with dementia are likely to be 
vulnerable to the harmful effects of DAPs such as cognitive 
decline (24). 
The aim of our study was to investigate the association 
between anticholinergic burden, defined by the Anticholinergic 
Risk Scale (ARS) (14), and HRQoL according to 15D (3). 
A second aim was to determine whether certain underlying 
conditions such as dementia, nutritional status or dependency 
on personal care have an interaction with the relationship 
between 15D and ARS score.  
Methods
All residents living in all long-term care facilities (including 
nursing homes and assisted living facilities) in Helsinki in 2017 
were invited to participate (N=3895).  Exclusion criteria were 
patient refusal, or having dementia and no proxy available 
to give informed consent.  Because the aim was to assess the 
burden arising from DAP use, we excluded residents not using 
regularly any medications or those whose medication list was 
not available.  After exclusions, 2474 participants remained.  
A trained, registered nurse performed the assessments and 
interviews according to a structured study protocol.  The data 
were collected in March 2017, and each resident was assessed 
over the course of one day. The medication list was a point-
prevalence on the same day. Medications were retrieved from 
participants’ medical charts.
All medications used were classified by the Anatomical 
Therapeutic Chemical (ATC) Classification System (25).  Only 
medications administered regularly were included. As described 
in previous research, regularly used drugs were considered to 
be those for which there was a documented regular sequence 
of administration (26). Thus, medications given pro re nata, 
were not taken into account.  DAPs were defined by the ARS, 
which is a list of 49 commonly used drugs with anticholinergic 
potential (14).  The ARS ranks medications on a 3-point scale 
(0=limited or none; 1=moderate; 2=strong; 3=very strong 
anticholinergic potential). The total ARS score is the sum of the 
points of individual medications.  However, the scale does not 
consider the dosage of an individual drug. Among older people, 
even a moderate change in the ARS score has been suggested 
to have an association with cognitive and functional decline 
(27); hence, we grouped the participants into four groups 
from none (G0) to very strong (G3) anticholinergic potential 
defined by the ARS to view also the participants with moderate 
anticholinergic burden.  The ARS has been used in several 
studies particularly involving nursing home residents, and it has 
been shown to have an association with outcomes in cognitive 
performance and physical function (9, 28, 29).
In each long-term care unit, background data on 
demographics, medical diagnoses (acute illnesses and chronic 
conditions) were retrieved from medical charts.
The severity of dementia was assessed by using the Clinical 
Dementia Rating (CDR) “memory” item [30] and the Mini 
Mental State Examination (MMSE) (31).  The CDR “memory” 
item grades stages of cognition on a 5-point scale (0=no 
memory loss; 0.5=consistent slight forgetfulness; 1=moderate 
memory loss; 2=severe memory loss; 3=severe memory 
loss, only fragments remain) (30).  MMSE is a screening 
tool for dementia, which also can be used in measuring 
cognitive impairment, yielding a score from 0 to 30 (31). 
Mini Nutritional Assessment (MNA) was applied to assess 
participants’ nutritional status (32).  Dependency in activities of 
daily living (ADL) was assessed by a 4-point scale according to 
the CDR “personal care” item (1=totally independent; 2=needs 
prompting; 3=requires assistance in dressing, personal hygiene, 
and keeping of personal belongings; 4=requires much help with 
personal care, often incontinent) (30).  Those in groups 3 and 4 
were considered to be dependent for personal care.
The main outcome of our study was HRQoL assessed by the 
15D instrument, which explores health state in 15 dimensions 
(mobility, vision, hearing, breathing, sleeping, eating, speech, 
excretion, usual activities, mental function, discomfort and 
symptoms, depression, distress, vitality, sexual activity) (3). 
The 15D is a validated instrument for use in various populations 
and health problems (3).  It is primarily meant to be filled in by 
the respondent, but interview or proxy administration is also 
possible.  15D can be generated to a 15D score as an index 
measure in which the minimum score is 0 (being dead) and the 
maximum score is 1 (no problems on any dimension) (3).
Statistics
The results are presented as means with standard deviations 
(SDs) or as counts with percentages. To evaluate the 
relationship of anticholinergic burden with HRQoL, we divided 
the participants into groups according to anticholinergic burden 
defined by ARS score (14) as follows: G0, ARS score=0; 
G1, ARS score=1; G2, ARS score=2; and G3, ARS score ≥3. 
Furthermore, we stratified the respective groups according 
to dementia diagnosis, nutritional status and dependency for 
personal care to investigate whether they have an interaction 
with the relationship between ARS score and HRQoL. 
Statistical significance for the unadjusted hypothesis 
of linearity across categories (quartiles) of ARS score and 
characteristics of the study participants were evaluated using 
the Cochran-Armitage test for trend, analysis of variance 
(ANOVA), and logistic (ordinal) models with an appropriate 
contrast. Adjusted (age, sex and CCI) relationship between 
ARS score and dementia diagnosis, nutritional status, and 
dependency in personal care with 15D was analyzed using two-
way analysis of variance.  In cases of violation of assumptions 
(e.g. non-normality), a bootstrap-type test was used. Normality 
of variables was evaluated graphically and using the Shapiro–
Wilk W test. Stata 16.1 (StataCorp LP, College Station, TX, 
USA) was used for the analysis.
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Results
The participants were divided into four groups according 
to the ARS score [G0 (n=1149); G1, (n=768); G2 (n=347); 
G3 (n=210)]. Of all participants, 1149 (46%) did not use any 
ARS-defined DAPs, and thus had an ARS score of 0 (G0); 
31% scored 1 point (G1), 14% 2 points (G2), and 8% 3 or 
more points (G3). A greater ARS score was associated with 
younger age and a lower proportion of females. Those having 
higher ARS scores suffered more often from depression, other 
psychiatric illnesses, and Parkinson’s disease.  The greater 
the ARS score, the greater the number of drugs used on a 
regular basis.  The number of ARS-defined drugs increased 
alongside greater anticholinergic burden; in G1, the mean 
number was 1.0, in G2 1.6, and in G3 2.1. The most frequently 
used ARS-defined drug groups were antipsychotics (33%) and 
antidepressants (23%).
Altogether, 1899 residents (77%) had a dementia diagnosis, 
whereas 575 (23%) did not.  Along with greater ARS scores, 
a decreasing trend in the proportion of participants with a 
diagnosis of dementia was observed: in G0 78%, in G1 82%, 
in G2 75%, and in G3 56% (p<0.001).  An increasing trend 
in MMSE points with greater ARS scores was observed, 
indicating better cognition, and CDR also suggested milder 
cognitive impairment with higher ARS scores.  Residents with 
higher ARS scores had better nutritional status than those 
with a lower ARS score.  A decreasing trend in dependency 
on personal care with a greater ARS score was observed. 
15D scores showed an increasing trend with ARS scores, 
thus indicating better HRQoL among those with a greater 
anticholinergic burden (Table 1).          
To further investigate whether cognitive or functional 
decline had an interaction with the relationship between ARS 
score and HRQoL, we then stratified the participants according 
to a diagnosis of dementia, nutritional status, and those 
dependent on personal care.  Between the ARS-score groups, 
significant differences in HRQoL were no longer observed. 
Overall, residents with dementia had lower 15D scores, 
indicating poorer HRQoL, versus those without dementia. 
Residents at risk of malnutrition or being malnourished had 
lower 15D scores than residents with good nutritional status 
(p<0.001), and the same pattern was observed in residents with 
Table 1










Females, n (%) 849(74) 574(75) 242(70) 142(68) 0.032
Age, years, mean (SDa) 83(8) 83(9) 82(9) 79(11) <0.001
Education <8 years, n (%) 443(39) 273(36) 138(40) 80(38) 0.97
Dementia, n (%) 896(78) 626(82) 260(75) 117(56) <0.001
Prior stroke, n (%) 296(26) 177(23) 63(18) 58(28) 0.21
Depression, n (%) 100(9) 99(13) 58(17) 41(20) <0.001
Other psychiatric diagnosis, n (%) 44(4) 68(9) 77(22) 65(31) <0.001
Parkinson disease, n (%) 37(3) 44(6) 36(10) 18(9) <0.001
Arthrosis and arthritis, n (%) 276(24) 176(23) 79(23) 39(19) 0.12
Diabetes mellitus, n (%) 233(20) 136(18) 68(20) 53(25) 0.38
Coronary heart disease, n (%) 238(21) 149(19) 62(18) 24(11) 0.004
MMSEb, mean (SDa) 12.7(7.4) 13.2(6.9) 13.6(6.9) 16.3(6.6) <0.001
MNAc, n (%) <0.001
  well-nourished (24-30 points) 156(15) 114(17) 71(22) 45(23)
  at risk for malnutrition (17-23.5 points) 667(64) 461(67) 209(66) 126(65)
  malnourished (<17 points) 221(21) 109(16) 36(11) 22(11)
Dependent for personal care (CDRd personal care class), n (%) 1017(91) 680(90) 297(87) 181(87) 0.015
Cognition (CDRd “memory” item), n (%) <0.001
   0-1 425(37) 297(39) 157(45) 123(59)
   2 329(30) 280(37) 115(34) 46(23)
   3 352(32) 173(23) 68(20) 32(16)
Number of drugs used regularly, mean (SDa) 7.8(3.5) 9.3(3.4) 9.8(3.3) 10.8(3.8) <0.001
15D score, mean (SDa) 0.596 (0.132) 0.619 (0.128) 0.626 (0.132) 0.629 (0.116) <0.001 
a. SD, standard deviation; b. MMSE, Mini Mental State Examination (31); c. MNA, Mini Nutritional Assessment (32); d. CDR, Clinical Dementia Rating (30)
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functional dependency compared with those not dependent 
on personal care (p<0.001).  Interactions between ARS score 
and dementia, and ARS score and dependency emerged, 
indicating different directions of trend in HRQoL in these 
two groups.  Among those with dementia or dependency, 
15D scores increased along with ARS scores, whereas they 
decreased among those without dementia and those who were 
not dependent. No significant interaction as regards nutritional 
status was observed (Figure 1).
Figure 1 
Relationship between anticholinergic burden measured by 
the Anticholinergic Risk Scale (ARS) score and health-
related quality of life (HRQoL) measured by 15D score 
among residents with and without dementia diagnosis; at 
risk for malnutrition or malnourished and well-nourished; 
and dependent and not dependent.  Adjusted for age, sex and 
Charlson Comorbidity Index (CCI)
We further explored the group of people with dementia. 
Among those with no anticholinergic burden (ARS score 0), 
the mean MMSE score was 11.2, whereas among those with 
dementia and ARS score ≥3, the respective figure was 13.7. Of 
those with dementia, most of the burden was associated with 
psychotropics, since 115/117 participants were on these drugs. 
Antipsychotic drugs were particularly common among them 
(80/117). Those without dementia suffered from psychiatric 
illnesses (n=46), stroke (n=24), Parkinson’s disease (n=8), 
or ALS/MS (n=7). Nearly all of them were administered 
psychotropics (92/93) as well.
Discussion
Our primary analysis suggested an association between 
higher anticholinergic burden and better health status in terms 
of cognition, nutrition, functioning and HRQoL. However, after 
stratification, no significant differences in HRQoL between 
the ARS-score groups remained. Furthermore, surprising 
interactions in the trends of 15D scores were observed in the 
groups stratified according to a diagnosis of dementia, and 
dependency as regards personal care.  Among residents with 
dementia or dependency, the trend in HRQoL scores increased 
with greater ARS score, whereas the trend was in the opposite 
direction among residents without dementia and those who 
were not dependent.      
The proportion of DAP users was consistent with those in 
earlier studies in which it has varied between 48% and 65% 
among nursing home residents (9, 33).  The ARS score was 
associated with a higher number of drugs used, which is also 
in line with observations in previous studies (9, 34).  We 
included only residents using at least one drug regularly, so the 
proportion of DAP users might be a slight overestimation of the 
true situation.  
In the primary analysis, our finding of an increasing trend 
of HRQoL along with increasing anticholinergic burden was 
surprising and not in line with the results of previous studies 
(5, 21-23). Hence, we further stratified our sample according 
to various health conditions, ARS scores and HRQoL.  After 
stratification and adjustments, the relationship between ARS 
score and HRQoL no longer existed. Irrespective of the 
ARS score, dementia, malnutrition and dependency were all 
associated with lower HRQoL, suggesting that these conditions 
are explanatory factors. These findings are in line with those in 
a prior study showing that the severity of dementia is associated 
with poorer QoL (35).  Our findings concerning the associations 
between poorer HRQoL and malnutrition or dependency are 
also supported by existing evidence from previous studies (36-
38).
The trend in ARS scores differed among those with and 
without dementia. Although it is challenging to determine 
whether it is the ARS score or the characteristics of participants 
that influences HRQoL, we explored the characteristics of 
our groups of participants. Those without dementia suffered 
from other psychiatric illnesses such as depression or chronic 
psychosis. Furthermore, almost all of them were administered 
psychotropic drugs. Thus, either the high burden of 
psychotropics is harmful in this patient group or the severity 
of these diseases has a negative impact on HRQoL. Because of 
the cross-sectional nature of the study it is impossible to draw 
definite conclusions on which explanation holds true.  
On the other hand, among those with dementia and 
dependency the 15D score increased along with anticholinergic 
burden. It seems that participants with dementia and higher 
ARS scores had better cognition and functioning, thus resulting 
in higher 15D scores. Thus, those with the most severe 
dementia might be spared a high anticholinergic burden. A 
large proportion of those with high ARS scores had been given 
psychotropics and antipsychotics, suggesting that they might 
suffer from neuropsychiatric symptoms. 
Our study has several strengths. To the best of our 
knowledge, it is the first one carried out in order to investigate 
the associations and interaction between anticholinergic burden, 
HRQoL and overall health status in connection with dementia, 
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nutritional status and functional dependency among residents 
living in long-term care facilities.  Our sample is large and well 
representative of older residents in long-term care in Helsinki. 
Because the medications were administered by nurses, drug use 
according to drug lists can be considered reliable.  Data were 
collected from residents’ medical records, and measurements 
were performed by trained nurses according to a standardized 
study protocol. The 15D instrument is a standardized and 
validated measure (3) showing high-level correlation with other 
HRQoL instruments such as EQ-5D and SF6D (39).   
As a limitation, the cross-sectional nature of our study allows 
us only to report associations within the cohort. Although 
interactions and associations exist between ARS score, HRQoL 
and cognitive decline, nutritional status and dependency, it is 
not possible to draw any conclusions about causal relationships. 
Thus, we must emphasize that confounding by indication may 
be behind the findings of our study. Cognitive impairment in 
our population was common, and thus the 15D questionnaire 
was mainly completed by an interviewer or via proxy 
administration.  Although caution in using a proxy respondent 
in measuring HRQoL has been suggested (40), the 15D 
instrument has been evaluated and shown to be reliable when 
used in this manner (3).  Proxy administration enabled us to 
include persons with severe dementia, in order to have a more 
real-life spectrum of nursing home residents. Another limitation 
is that we used only one anticholinergic scale. While a number 
of scales exist, there is considerable discordance between them. 
Thus, the results and outcomes might have been different had 
a scale other than the ARS been used (28, 29).  However, the 
ARS scale is widely used, particularly among nursing home 
residents (29).
Conclusion
Whereas in the primary analysis there was an association 
between anticholinergic burden defined by the ARS, and 
HRQoL measured by the 15D instrument, this relationship 
disappeared when the participants were stratified according 
to dementia, nutritional status and dependency. Interaction 
in the dementia and dependency groups was observed. The 
reasons behind this interaction remain unclear, warranting 
further studies.  
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